{"prompt": "['Product: MK-3475', '124', 'Protocol/Amendment No.: 604-09', '[8]', 'Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical', 'significance and therapeutic potential of the programmed death-1', 'ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res', '2007;13(7):2151-7.', '[9]', 'Gao Q, Wang X-Y, Qiu S-J, Yamato I, Sho M, Nakajima Y, et al. Overexpression', 'of PD-L1 significantly associates with tumor aggressiveness and postoperative', 'recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15(3):971-9', '[10]', 'Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al.', 'Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are', 'prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A', '2007;104(9):3360-5.', '[11]', 'Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a', 'regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J', 'Immunol 2009;182:5240-9.', '[12]', 'Cai G, Karni A, Oliveira EML, Weiner HL, Hafler DA, Freeman GJ. PD-1', 'ligands, negative regulators for activation of na\u00efve, memory, and recently', 'activated human CD4+ T cells. Cell Immunol 2004;230(2):89-98', '[13]', 'Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell', 'exhaustion: an update on implications for chronic infections and tumor evasion.', 'Cancer Immunol Immunother. 2007 May;56(5):739-45.', '[14]', 'Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-', 'L1 on tumor cells in the escape from host immune system and tumor', 'immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A', '2002;99(19): 12293-7.', '[15]', 'Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, et al.', 'Predominant expression of B7-H1 and its immunoregulatory roles in oral', 'squamous cell carcinoma. Oral Oncol 2006;42:268-74.', '[16]', 'Korman A, Chen B, Wang C, Wu L, Cardarelli P, Selby M. Activity of anti-PD-1', 'in murine tumor models: role of \"host\" PD-L1 and synergistic effect of anti-PD-1', 'and anti-CTLA-4 [Abstract]. J Immunol 2007;178:48.37.', '[17]', 'Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance', 'of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009 Apr', '2;9:3.', '[18]', 'Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et', 'al. Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer. N', 'Engl J Med. \"in press\" 2012.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '125', 'Protocol/Amendment No.: 604-09', '[19]', 'Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al.', '2012 ASCO Annual Meeting: Phase I study of MK-3475 (anti-PD-1 monoclonal', 'antibody) in patients with advanced solid tumors.', '[20]', \"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.\", 'Improved survival with ipilimumab in patients with metastatic melanoma. N Engl', 'J Med 2010;363(8):711-23.', '[21]', 'Chapman PB, Hauschild A, Robert C, Hannen JB, Ascierto P, Larkin J, et al.', 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N', 'Engl J Med 2011;364(26):2507-16', '[22]', \"Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab\", 'plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med', '2011;364(26):2517-26.', '[23]', 'Bellati F, Visconti V, Napoletano C, Antonilli M, Frati L, Benedetti Panici P, et al.', 'Immunology of gynecologic neoplasms: analysis of the prognostic significance of', 'the immune status. Curr Cancer Drug Targets 2009;9(4):541-65.', '[24]', 'Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer', 'development: polarization towards pro-tumor immunity. Cytokine Growth Factor', 'Rev 2010;21:3-10.', '[25]', 'Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor-', 'infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical', 'management. Int J Clin Oncol 2010;15:552-8.', '[26]', 'Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund L-T. The', 'prognistic value of intraepithelial and stromal CD3-, CD117- and CD138-positive', 'cells in non-small cell lung carcinoma. APMIS 2010;118:371-82.', '[27]', 'Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic', 'adenocarcinoma: insights from genetically engineered mouse models of cancer.', 'Cancer Lett 2009;279:1-7.', '[28]', 'Diederichsen ACP, Hjelmborg JvB, Christensen PB, Zeuthen J, Fenger C.', 'Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in', 'colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol', 'Immunother 2003;52:423-8.', '[29]', 'Gao Q, Qiu S-J, Fan J, Zhou J, Wang X-Y, Xiao Y-S, et al. Intratumoral balance', 'of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular', 'carcinoma after resection. J Clin Oncol 2007;25(18):2586-93', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}